Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gαi/o protein inhibitor

被引:24
作者
Porcu, Alessandra [1 ,2 ]
Melis, Miriam [1 ]
Turecek, Rostislav [2 ]
Ullrich, Celine [2 ]
Mocci, Ignazia [3 ]
Bettler, Bernhard [2 ]
Gessa, Gian Luigi [1 ,4 ,5 ,6 ]
Castelli, M. Paola [1 ,6 ]
机构
[1] Univ Cagliari, Dept Biomed Sci, I-09042 Monserrato, Italy
[2] Univ Basel, Dept Biomed, Klingelbergstr 50-70, CH-4056 Basel, Switzerland
[3] UOS Cagliari, Natl Res Council Italy CNR, Inst Translat Pharmacol, I-09010 Pula, Italy
[4] Univ Cagliari, Guy Everett Lab, I-09042 Monserrato, Italy
[5] Natl Res Council Italy CNR, Neurosci Inst, Cagliari, Italy
[6] Univ Cagliari, Ctr Excellence Neurobiol Addict, I-09042 Monserrato, Italy
基金
瑞士国家科学基金会;
关键词
Bioluminescence resonance energy transfer (BRET); Cannabinoid receptor type 1 (CB1); CB1-receptor antagonist; Inverse agonist; G protein; G protein-coupled receptor (GPCR); BETA-GAMMA-SUBUNITS; INVERSE AGONISM; CONSTITUTIVE ACTIVITY; CARDIOMETABOLIC RISK; BLOCKER RIMONABANT; SIGNALING PROTEINS; LIGAND-BINDING; G-ALPHA; GABA-B; DRUG;
D O I
10.1016/j.neuropharm.2018.01.024
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rimonabant is a potent and selective cannabinoid CB1 receptor antagonist widely used in animal and clinical studies. Besides its antagonistic properties, numerous studies have shown that, at micromolar concentrations rimonabant behaves as an inverse agonist at CB1 receptors. The mechanism underpinning this activity is unclear. Here we show that micromolar concentrations of rimonabant inhibited G alpha(i/o)-type G proteins, resulting in a receptor-independent block of G protein signaling. Accordingly, rimonabant decreased basal and agonist stimulated [S-35]GTP gamma S binding to cortical membranes of CB1- and GABA(B)-receptor KO mice and Chinese Hamster Ovary (CHO) cell membranes stably transfected with GABA(B) or D2 dopamine receptors. The structural analog of rimonabant, AM251, decreased basal and baclofen-stimulated GTP gamma S binding to rat cortical and CHO cell membranes expressing GABA(B) receptors. Rimonabant prevented G protein-mediated GABA(B) and D2 dopamine receptor signaling to adenylyl cyclase in Human Embryonic Kidney 293 cells and to G protein-coupled inwardly rectifying K+ channels (GIRK) in midbrain dopamine neurons of CB1 KO mice. Rimonabant suppressed GIRK gating induced by GTP gamma S in CHO cells transfected with GIRK, consistent with a receptor-independent action. Bioluminescent resonance energy transfer (BRET) measurements in living CHO cells showed that, in presence or absence of co-expressed GABA(B) receptors, rimonabant stabilized the heterotrimeric GG alpha(i/o)-protein complex and prevented conformational rearrangements induced by GABA(B) receptor activation. Rimonabant failed to inhibit G alpha s-mediated signaling, supporting its specificity for GG alpha(i/o)-type G proteins. The inhibition of GG alpha(i/o) protein provides a new site of rimonabant action that may help to understand its pharmacological and toxicological effects occurring at high concentrations. (C) 2018 Elsevier Ltd. All rights reserved.
引用
收藏
页码:107 / 120
页数:14
相关论文
共 76 条
[1]  
Ahmad Sultan, 2004, Curr Opin Investig Drugs, V5, P67
[2]   Inhibition of Heterotrimeric G Protein Signaling by a Small Molecule Acting on Gα Subunit [J].
Ayoub, Mohammed Akli ;
Damian, Marjorie ;
Gespach, Christian ;
Ferrandis, Eric ;
Lavergne, Olivier ;
De Wever, Olivier ;
Baneres, Jean-Louis ;
Pin, Jean-Philippe ;
Prevost, Gregoire Pierre .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (42) :29136-29145
[3]   Blood, adipose tissue and brain levels of the cannabinoid ligands WIN-55,212 and SR-141716A after their intraperitoneal injection in mice: Compound-specific and area-specific distribution within the brain [J].
Barna, I. ;
Till, I. ;
Haller, J. .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 (08) :533-541
[4]   SR-141716A-induced stimulation of locomotor activity - A structure-activity relationship study [J].
Bass, CE ;
Griffin, G ;
Grier, M ;
Mahadevan, A ;
Razdan, RK ;
Martin, BR .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2002, 74 (01) :31-40
[5]   Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders [J].
Beardsley, Patrick M. ;
Thomas, Brian F. ;
Mcmahon, Lance R. .
INTERNATIONAL REVIEW OF PSYCHIATRY, 2009, 21 (02) :134-142
[6]   Rimonabant: Just an Antiobesity drug? Current evidence on its pleiotropic effects [J].
Bifulco, Maurizio ;
Grimaldi, Claudia ;
Gazzerro, Patrizia ;
Pisanti, Simona ;
Santoro, Antonietta .
MOLECULAR PHARMACOLOGY, 2007, 71 (06) :1445-1456
[7]   Differential targeting of Gβγ-subunit signaling with small molecules [J].
Bonacci, TM ;
Mathews, JL ;
Yuan, CJ ;
Lehmann, DM ;
Malik, S ;
Wu, DQ ;
Font, JL ;
Bidlack, JM ;
Smrcka, AV .
SCIENCE, 2006, 312 (5772) :443-446
[8]   Evidence for a new G protein-coupled cannabinoid receptor in mouse brain [J].
Breivogel, CS ;
Griffin, G ;
Di Marzo, V ;
Martin, BR .
MOLECULAR PHARMACOLOGY, 2001, 60 (01) :155-163
[9]   Cannabinoid type I receptor antagonists for smoking cessation [J].
Cahill, K. ;
Ussher, M. H. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (03)
[10]   Rapid tolerance to the intestinal prokinetic effect of cannabinoid CB1 receptor antagonist, SR 141716 (Rimonabant) [J].
Carai, MAM ;
Colombo, G ;
Gessa, GL .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 494 (2-3) :221-224